# Exercise therapy to improve mobility, active behaviour and quality of life of chronic kidney disease patients with peripheral artery disease: study protocol for the EXACT-CKDPAD multicentre randomised controlled trial

**Authors:** Fabio Manfredini, Vincenzo Panuccio, Yuri Battaglia, Alda Storari, Nicola Lamberti, Giovanni Piva, Marco Veronesi, Rocco Tripepi, Natascia Rinaldo, Anna Crepaldi, Claudia Momentè, Angela Piccinini, Luca Traina, Aaron Thomas Fargion, Sofia Straudi, Andrea Baroni, Alfredo De Giorgi, Carlotta Martinuzzi, Marcello Monesi, Alessandro Capitanini, Filippo Aucella, Adamasco Cupisti, Francesca Mallamaci, Carmine Zoccali, Roberto Manfredini

PMC · DOI: 10.1136/bmjsem-2025-002740 · BMJ Open Sport & Exercise Medicine · 2025-07-15

## TL;DR

This study tests a home-based walking exercise program to improve mobility and quality of life for patients with chronic kidney disease and peripheral artery disease.

## Contribution

The study is the first to specifically test exercise therapy in patients with CKD and PAD.

## Key findings

- A 6-month interval walking program will be tested for CKD-PAD patients.
- Primary outcome is the 6-minute walking distance, with secondary outcomes including quality of life and physical strength.
- Results may validate a home-based, pain-free exercise intervention for this high-risk population.

## Abstract

The combination of chronic kidney disease (CKD) and peripheral artery disease (PAD) enhances the already present high cardiovascular risk, exposing the affected patients to unfavourable long-term clinical outcomes. Physical exercise is considered an effective treatment for reducing sedentary behaviour and improving quality of life, but several barriers limit patient participation. In this parallel-design, single-blinded, randomised controlled trial, we will enrol 130 patients with concomitant CKD at stages III and IV and PAD at the claudication stage to be randomised into a 6-month exercise (Ex) or control (Co) intervention. The Ex programme will consist of two daily 10 min interval walking sessions (1 min of walking followed by 1 min of resting), with gait speed controlled via a metronome and increased approximately weekly. The Co group will receive standard nephrological care. Outcomes will be assessed before and after treatment, as well as at the 12-month follow-up. The primary outcome will be the 6 min walking distance. The secondary outcomes will include quality of life, lower limb and handgrip strength, body composition and bone mineral density, as well as circulating indexes of kidney function and long-term clinical outcomes. Since no trials have been published that purposely enrol this high-risk population (CKD-PAD), the eventual positive results will validate a simple, pain-free exercise intervention that can be carried out at home to improve patients’ mobility and quality of life. Trial registration number: NCT06621264.

## Linked entities

- **Diseases:** chronic kidney disease (MONDO:0005300)

## Full-text entities

- **Diseases:** pain (MESH:D010146), CKD (MESH:D051436), PAD (MESH:D058729), claudication (MESH:D007383)
- **Species:** Homo sapiens (human, species) [taxon 9606]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12265826/full.md

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12265826/full.md

## References

47 references — full list in the complete paper: https://tomesphere.com/paper/PMC12265826/full.md

---
Source: https://tomesphere.com/paper/PMC12265826